Palisade Bio Says Ulcerative Colitis Patients Respond to PALI-2108 Treatment in Phase 1b Trial

MT Newswires Live

2025/09/17

Palisade Bio (PALI) said Wednesday that a phase 1b trial of its investigational drug PALI-2108 in ulcerative colitis showed 100% clinical response, with all five patients responding to treatment.

The study also showed "promising" efficacy data, with two of the five patients achieving clinical remission after seven days based on US Food and Drug Administration-defined endpoints, the company said.

PALI-2108 also showed a "favorable" safety profile and support anti-fibrotic activity, expanding development potential into fibrostenotic Crohn's disease, Palisade said.

The company said it expects to begin patient dosing in a phase 1b trial in fibrostenotic Crohn's disease within the year and targets to file in H1 of 2026 an investigational new drug application for a phase 2 trial.

Palisade shares were up more than 4% in recent trading Wednesday.

Price: 0.63, Change: +0.03, Percent Change: +4.58

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2568494530"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2568494530\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2568494530?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-17 21:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2568494530","market":"sg","top_or_hot":-1,"title":"Palisade Bio Says Ulcerative Colitis Patients Respond to PALI-2108 Treatment in Phase 1b Trial","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/PALI\">Palisade Bio</a> (PALI) said Wednesday that a phase 1b trial of its investigational drug PALI-2108 in ulcerative colitis showed 100% clinical response, with all five patients responding to treatment.</p><p>The study also showed \"promising\" efficacy data, with two of the five patients achieving clinical remission after seven days based on US Food and Drug Administration-defined endpoints, the company said.</p><p>PALI-2108 also showed a \"favorable\" safety profile and support anti-fibrotic activity, expanding development potential into fibrostenotic Crohn's disease, Palisade said.</p><p>The company said it expects to begin patient dosing in a phase 1b trial in fibrostenotic Crohn's disease within the year and targets to file in H1 of 2026 an investigational new drug application for a phase 2 trial.</p><p>Palisade shares were up more than 4% in recent trading Wednesday.</p><p>Price: 0.63, Change: +0.03, Percent Change: +4.58</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palisade Bio Says Ulcerative Colitis Patients Respond to PALI-2108 Treatment in Phase 1b Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalisade Bio Says Ulcerative Colitis Patients Respond to PALI-2108 Treatment in Phase 1b Trial\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-09-17 21:53</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/PALI\">Palisade Bio</a> (PALI) said Wednesday that a phase 1b trial of its investigational drug PALI-2108 in ulcerative colitis showed 100% clinical response, with all five patients responding to treatment.</p><p>The study also showed \"promising\" efficacy data, with two of the five patients achieving clinical remission after seven days based on US Food and Drug Administration-defined endpoints, the company said.</p><p>PALI-2108 also showed a \"favorable\" safety profile and support anti-fibrotic activity, expanding development potential into fibrostenotic Crohn's disease, Palisade said.</p><p>The company said it expects to begin patient dosing in a phase 1b trial in fibrostenotic Crohn's disease within the year and targets to file in H1 of 2026 an investigational new drug application for a phase 2 trial.</p><p>Palisade shares were up more than 4% in recent trading Wednesday.</p><p>Price: 0.63, Change: +0.03, Percent Change: +4.58</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PALI","symbol_name":"Palisade Bio Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2568494530","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2568494530","pubTimestamp":1758117195,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Palisade Bio  said Wednesday that a phase 1b trial of its investigational drug PALI-2108 in ulcerative colitis showed 100% clinical response, with all five patients responding to treatment.The study also showed \"promising\" efficacy data, with two of the five patients achieving clinical remission after seven days based on US Food and Drug Administration-defined endpoints, the company said.PALI-2108 also showed a \"favorable\" safety profile and support anti-fibrotic activity, expanding development potential into fibrostenotic Crohn's disease, Palisade said.The company said it expects to begin patient dosing in a phase 1b trial in fibrostenotic Crohn's disease within the year and targets to file in H1 of 2026 an investigational new drug application for a phase 2 trial.Palisade shares were up more than 4% in recent trading Wednesday.Price: 0.63, Change: +0.03, Percent Change: +4.58","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PALI":"Palisade Bio Inc.","BK4007":"制药","BK4139":"生物科技"},"translate_title":"Palisade Bio称溃疡性结肠炎患者在1b期试验中对PALI-2108治疗有反应","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PALI":1.5},"content_text":"Palisade Bio (PALI) said Wednesday that a phase 1b trial of its investigational drug PALI-2108 in ulcerative colitis showed 100% clinical response, with all five patients responding to treatment.The study also showed \"promising\" efficacy data, with two of the five patients achieving clinical remission after seven days based on US Food and Drug Administration-defined endpoints, the company said.PALI-2108 also showed a \"favorable\" safety profile and support anti-fibrotic activity, expanding development potential into fibrostenotic Crohn's disease, Palisade said.The company said it expects to begin patient dosing in a phase 1b trial in fibrostenotic Crohn's disease within the year and targets to file in H1 of 2026 an investigational new drug application for a phase 2 trial.Palisade shares were up more than 4% in recent trading Wednesday.Price: 0.63, Change: +0.03, Percent Change: +4.58","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}